Table 2.
Parameter | Category | No. patients † | Response rate (%) ‡ | P‐value |
---|---|---|---|---|
ER | Positive | 32 | 56 | 0.862 |
Negative | 37 | 57 | ||
HER2 | Positive | 13 | 69 | 0.193 |
Negative | 49 | 49 | ||
P‐glycoprotein | Positive | 26 | 54 | 0.987 |
Negative | 37 | 54 | ||
MIB‐1 | Positive | 39 | 49 | 0.354 |
Negative | 23 | 60 | ||
BRCA1 | Positive | 47 | 53 | 0.794 |
Negative | 14 | 57 | ||
BCL2 | Positive | 17 | 70 | 0.144 |
Negative | 46 | 50 | ||
p53 | Positive | 29 | 55 | 0.961 |
Negative | 33 | 54 | ||
β‐Tubulin III | Positive | 14 | 28 | <0.05 |
Negative | 42 | 59 | ||
CYP3A4 | Positive | 16 | 19 | <0.01 |
Negative | 15 | 67 | ||
Thioredoxin | Positive | 14 | 21 | 0.018 |
Negative | 49 | 63 |
Patients with large primary breast cancers or locally recurrent breast cancers.
‡ Patients who showed a complete or partial clinical response were considered to be responders.